TY - JOUR
T1 - Intravascular ultrasound assessment of novel antiatherosclerotic therapies
T2 - Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study
AU - Nicholls, Stephen J.
AU - Sipahi, Ilke
AU - Schoenhagen, Paul
AU - Wisniewski, Lisa
AU - Churchill, Tammy
AU - Crowe, Timothy
AU - Goormastic, Marlene
AU - Wolski, Kathy
AU - Tuzcu, E. Murat
AU - Nissen, Steven E.
PY - 2006/7
Y1 - 2006/7
N2 - Background: Inhibiting the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) has beneficial effects on foam cell formation and therefore has the potential to favorably influence the progression of coronary atherosclerosis. The aim of this study is to determine whether ACAT inhibition, when added to usual medical care, reduces atheroma progression in subjects with coronary artery disease. Methods: Five hundred thirty-four subjects with established coronary artery disease on angiography were randomized to receive the experimental ACAT inhibitor, pactimibe, 100 mg daily or matching placebo for 18 months. The primary efficacy parameter will be the nominal change in percent atheroma volume determined by analysis of pullback intravascular ultrasound (IVUS) images of matched coronary artery segments acquired at baseline and 18-month follow-up. In addition, the effect of pactimibe on plasma lipids and inflammatory markers and the incidence of clinical cardiovascular events will also be assessed. Conclusion: Serial IVUS has emerged as a sensitive imaging modality to assess the impact that novel antiatherosclerotic strategies have on the arterial wall. In this study, IVUS will be used to assess whether ACAT inhibition modifies progression of atherosclerotic plaque.
AB - Background: Inhibiting the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) has beneficial effects on foam cell formation and therefore has the potential to favorably influence the progression of coronary atherosclerosis. The aim of this study is to determine whether ACAT inhibition, when added to usual medical care, reduces atheroma progression in subjects with coronary artery disease. Methods: Five hundred thirty-four subjects with established coronary artery disease on angiography were randomized to receive the experimental ACAT inhibitor, pactimibe, 100 mg daily or matching placebo for 18 months. The primary efficacy parameter will be the nominal change in percent atheroma volume determined by analysis of pullback intravascular ultrasound (IVUS) images of matched coronary artery segments acquired at baseline and 18-month follow-up. In addition, the effect of pactimibe on plasma lipids and inflammatory markers and the incidence of clinical cardiovascular events will also be assessed. Conclusion: Serial IVUS has emerged as a sensitive imaging modality to assess the impact that novel antiatherosclerotic strategies have on the arterial wall. In this study, IVUS will be used to assess whether ACAT inhibition modifies progression of atherosclerotic plaque.
UR - http://www.scopus.com/inward/record.url?scp=32044460549&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2005.10.025
DO - 10.1016/j.ahj.2005.10.025
M3 - Article
C2 - 16824833
AN - SCOPUS:32044460549
SN - 0002-8703
VL - 152
SP - 67
EP - 74
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -